News

Our Healthcare News

EyePoint Pharmaceuticals Receives FDA Approval of YUTIQ (fluocinolone acetonide intravitreal implant) 0.18 mg

The first long-lasting, FDA approved micro-insert for up to three years of continuous control in chronic, non-infectious posterior segment uveitis, the third leading cause of…  

Oct 15 2018

Corium Announces Agreement for Gurnet Point Capital to Purchase All Outstanding Shares

Total Transaction Valued in Excess of $500 Million, Representing a 50% Premium

Gurnet Point Capital to Expand Operations While Focusing on the Approval and Commercialization…  

Oct 11 2018

EW Healthcare Partners Announces the Appointment of Two Senior Executives

NEW YORK, New York – EW Healthcare Partners (“EW”), a leading healthcare growth equity firm with a global investment practice, has announced the addition of…  

Oct 10 2018

EUSA Pharma Announces Acquisition of Global Rights to SYLVANT (siltuximab) from Janssen Sciences Ireland UC for $115 Million

Acquisition significantly boosts EUSA Pharma’s presence as a global biopharmaceutical company in oncology and rare diseases

SYLVANT is the only FDA and EMA approved treatment…  

Jul 18 2018

AxoGen Chairman and CEO Karen Zaderej Named Entrepreneur of the Year 2018 Award Winner in Florida

ALACHUA, Florida—(GLOBE NEWSWIRE)—AxoGen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerves, today announced that Ernst & Young (EY)…  

Jun 08 2018

AxoGen, Inc Announces Upsizing and Pricing of Public Offering of Common Stock

ALACHUA, Florida (GLOBE NEWSWIRE)—AxoGen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerves, announced today that it has priced…  

May 09 2018

Encore Dermatology, Inc. Announces the Launch of IMPOYZ (clobetasol propionate) Cream, 0.025%, a Newly Formulated High-Potency Topical Corticosteroid

MALVERN, Pennsylvania—Encore Dermatology Inc. announces today the availability of a new topical product, IMPOYZ Cream, indicated for the treatment of moderate to severe plaque psoriasis…  

May 01 2018

pSivida Corp. Announces Transformative Acquisition of Icon Bioscience Inc. and Growth Capital Financing with Essex Woodlands Healthcare Partners - Company will Rebrand as EyePoint Pharmaceuticals, Inc.

WATERTOWN, Massachusetts(GLOBE NEWSWIRE)—pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced the acquisition of Icon Bioscience…  

Mar 28 2018

EUSA Pharma Appoints Industry Veteran Rolf K Hoffmann to its Board of Directors

HEMEL HEMPSTEAD, England –– EUSA Pharma (EUSA), a world-class specialty pharmaceutical company focused on oncology and oncology supportive care, today announced the appointment of Rolf…  

Mar 07 2018



View Legacy Fund news >